CANDIDURIA IN IMMUNOCOMPROMISED INDIVIDUALS IN A TERTIARY CARE CENTER IN NORTHERN INDIA

  • Ved Prakash Associate Professor, Dept of Microbiology, RMCH, Bareilly, U.P
  • Prem Prakash Assistant Professor, Dept of Microbiology, RMCH, Bareilly, U.P
  • Dakshina Bisht Professor, Dept of Microbiology, Santosh Medical College, Ghaziabad, U.P
  • Shashikant V Professor, Dept of Physiology, RMCH, Bareilly, U.P
  • H. K. Premi Professor, Dept of Obst & Gynae, RMCH, Bareilly, U.P
  • D. Tripathi Assistant Professor, Dept of Medicine, RMCH, Bareilly, U.P
Keywords: Candida, immunocompromised, antifungal, invasive procedures

Abstract

Fungal infections of the urinary tract, caused by Candida species, are becoming prevalent worldwide. The aim of our study was to determine the prevalence of candiduria in immunocompromised patients in our hospital. During a period of 1 year, a total of 418 urine samples were collected and transported to the Department of Microbiology. After direct microscopic examination, the samples were inoculated onto Sabaraud’s Dextrose agar with antibiotics. The Candida albicans and non-albicans were identified by colony morphology, Germ tube test, and Chlamydospore formation test on Corn Meal agar. The antifungal sensitivity testing was done by the Disc diffusion method. Out of 418 samples {174(41.62%) males and 244 (58.37%) females} Candida species has been isolated from 78 (18.66%) cases. Out of the 78 (100 %) isolates, 47 (60.25%) were Candida albicans and 31 (39.74%) were non-albicans species. The age ranged from sixteen months to 86 years. Various risk factors observed among the patients were long duration of hospitalization, catheter use, antimicrobial therapy/chemotherapy, diabetes mellitus, HIV, etc. Amphotericin B and Itraconazole were the most sensitive antifungal agents. However, more resistance was seen in the case of non-albicans Candida species against the same antibiotics. In conclusion, candiduria is relatively common in immunocompromised patients both by Candida albicans as well as non-albicans species. In addition, there is a strong correlation between the incidence of candiduria in immunocompromised patients and broad-factors impairing the immunity of patients. There is a rise in resistance against the antifungal agents for both Candida albicans and non-albicans species.

Downloads

Download data is not yet available.

References

1. Bukhary ZA. Candiduria: a review of clinical significance and management. Saudi J Kidney Dis Transpl 2008; 19:350-360.
2. Achkar JM, Fries BC. Candida Infections of the Genitourinary Tract. Clin Microbiol Rev 2010; 23: 253-273.
3. Sellami A, Sellami H, Makni F, Bahloul M, Cheikh-Rouhou F, Bouaziz M, Ayadi A. Candiduria in intensive care unit: significance and value of yeast numeration in the urine. Ann Fr Anesth Reanim 2006; 25: 584-588.
4. Yang YL, Cheng MF, Chang YW, Young TG, Chi H, Lee SC, et al. Host factors do not influence the colonization or infection by fluconazole-resistant Candida species in hospitalized patients. J Negative Results in BioMed 2008; 7: 12.
5. Kauffman CA, Vazquez JA, Sobel JD, et al. Prospective multicenter surveillance study of funguria in hospitalized patients. Clin Infect Dis 2000; 30:14–8.
6. Ayeni O, Riederer KM, Wilson FM, Khatib R. Clinicians’ reaction to positive urine culture for Candida organisms. Mycoses 1999; 42:285–9.
7. Storfer SP, Medoff G, Fraser VJ, Powderly WG, Dunagan WC. Candiduria: retrospective review in hospitalized patients. Infect Dis Clin Pract 1994; 3:23–9.
8. Schoenbeck J. Studies on Candida infection of the urinary tract and on the antimycotic drug 5-fluorocytosine. Scand J Urol Nephrol Suppl 1972; 11:7–48.
9. Rex JH, Pfaller MA, Walsh TJ, Chaturvedi V, Espinel-Ingroff A, Ghannoum MA, et al. Antifungal Susceptibility Testing: Practical Aspects and Current Challenges. Clin Microbiol Rev 2001; 14:643–58.
10. Nayman Alpat S, Özguneş I, Ertem 1. OT, Erben N, Doyuk Kartal E, Tözun M, et al. Evaluation of risk factors in patients with candiduria. Mikrobiyol Bul 2011; 45: 318-324.
11. Jain N, Kohli R, Cook E, Gialanella P, Chang T, Fries BC. Biofilm formation by and antifungal susceptibility of Candida isolates from urine. Appl Environ Microbiol 2007; 73: 1697-1703.
12. Achkar JM, Fries BC. Candida Infections of the Genitourinary Tract. Clin Microbiol Rev 2010; 23: 253-273.
13. Zarei-Mahmoudabadi A, Zarrin M, Ghanatir F, Vazirianzadeh B. Iran. J. Microbiol 2012; 4: 198-203.
14. Kauffman CA, Vazquez JA, Sobel JD, et al. Prospective multicenter surveillance study of funguria in hospitalized patients. Clin Infect Dis 2000; 30:14–8.
15. Ayeni O, Riederer KM, Wilson FM, Khatib R. Clinicians’ reaction to positive urine culture for Candida organisms. Mycoses 1999; 42:285–9.
16. Harris AD, Castro J, Sheppard DC, Carmeli Y, Samore MH. Risk factors for nosocomial candiduria due to Candida glabrata and Candida albicans. Clin Infect Dis 1999; 29:926–8.
17. Joanne L. May, Anna King, and Christine A. Warren. Fluconazole disc diffusion testing for the routine laboratory. Journal of Antimicrobial Chemotherapy 1997; 40, 511–516.
18. P Badiee, A Alborzi. Susceptibility of clinical Candida species isolates to antifungal agents by E-test, Southern Iran: A five-year study. Iran J Microbiol 2011; 3(4): 183–188.
19. Bauters TG, Dhont MA, Temmerman MI, Nelis HJ. Prevalence of vulvovaginal candidiasis and susceptibility to fluconazole in women. Am J Obstet Gynecol. 2002; 187:569–574.
20. Citak S, Ozçelik B, Cesur S, Abbasoğlu U. In vitro susceptibility of Candida isolated from blood culture to some antifungal agents. Jpn J Infect Dis 2005; 58:44–46.
How to Cite
1.
Prakash V, Prakash P, Bisht D, V S, Premi HK, Tripathi D. CANDIDURIA IN IMMUNOCOMPROMISED INDIVIDUALS IN A TERTIARY CARE CENTER IN NORTHERN INDIA. Med. res. chronicles [Internet]. 2015Mar.15 [cited 2024Nov.22];2(2):176-82. Available from: https://medrech.com/index.php/medrech/article/view/67
Issue
Vol. 2 No. 2 (2015): Mar-Apr
Section
Original Research Article